Understanding the mechanism by which cell growth, migration, polyploidy, and tumorigenesis are regulated may provide important therapeutic strategies for cancer therapy. Here we identify the Skp2–macroH2A1 (mH2A1)–cyclin-dependent kinase 8 (CDK8) axis as a critical pathway for these processes, and deregulation of this pathway is associated with human breast cancer progression and patient survival outcome. We showed that mH2A1 is a new substrate of Skp2 SCF complex whose degradation by Skp2 promotes CDK8 gene and protein expression. Strikingly, breast tumour suppression on Skp2 deficiency can be rescued by mH2A1 knockdown or CDK8 restoration using mouse tumour models. We further show that CDK8 regulates p27 protein expression by facilitating Skp2-mediated p27 ubiquitination and degradation. Our study establishes a critical role of Skp2–mH2A1–CDK8 axis in breast cancer development and targeting this pathway offers a promising strategy for breast cancer therapy. Skp2 forms part of the SCF complex—an E3 ubiquitin ligase. Here the authors identify macroH2A1 as a novel target of Skp2 and propose an axis of regulation involving Skp2-macroH2A1-CDK8-p27 in cancer.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: